BLPH

Bellerophon Therapeutics Inc

NASDAQ

Add Alert

BLPH

Bellerophon Therapeutics Inc

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

delerious1 PremiumMember

11/15/23 11:20 AM

Post #745

Will this company ever start again...did the study find anything positive out of all their data?

Did they go as far as bankruptcy?

Renee

10/13/23 5:00 PM

Post #744

BLPH delisted from the Nasdaq to the OTC. ***PPS dropped 68% from .39 to .1235 on ~14 million volume.

https://otce.finra.org/otce/dailyList?viewType=Additions

willlbone

10/13/23 1:24 PM

Post #743

ten cents

Awl416

10/13/23 10:31 AM

Post #742

RIP…

maestro_of_Ihub Free

07/25/23 8:33 AM

Post #741

We all knew 33 cents was capitulation here! Congrats on those that waited and loaded with the maestro posse! Easy 10 banger here from those levels over next 36 months! Enjoy the ride, it will be bumpy but very profitable as always! 💪🏿😈

Awl416

07/25/23 6:26 AM

Post #740

Yikes

Law of Averages Free

07/11/23 3:30 PM

Post #739

This one is gonna run hard BB bands are pinched very tight.

Bullish

kingsransome Free

06/05/23 1:04 PM

Post #738

Re: #737: @Awl416 - What happened?

failed trial

Awl416

06/05/23 11:44 AM

Post #737

What happened?

delerious1 PremiumMember

05/15/23 8:13 PM

Post #736

NEWS

Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results
May 15, 2023 16:50 ET | Source: Bellerophon Therapeutics, Inc.

Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023
WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2023.

“We are pleased with the progress we have made to date in 2023, highlighted by the completion of the blinded treatment phase of our ongoing pivotal Phase 3 REBUILD trial,” said Peter Fernandes, Bellerophon’s Chief Executive Officer. “We expect to report top-line results from the study in the middle of this year, a critical milestone for the Company. Importantly, following the recent license agreement with Baylor Bioscience and having successfully completed a $5 million equity financing, we are well-capitalized through this critical milestone.”

Clinical Program Highlights:

Fibrotic Interstitial Lung Disease (fILD)

REBUILD Phase 3 Study: The Company completed the blinded treatment phase of their pivotal Phase 3 REBUILD trial evaluating the safety and efficacy of INOpulse® for the treatment of patients with fILD and anticipates the availability of top-line results in mid-2023. A total of 145 fILD patients were enrolled and treated with either INOpulse at a dose of iNO45 or placebo. The Phase 3 program builds on positive top-line results from the Company’s previously reported Phase 2 studies for INOpulse® for the treatment of fILD which showed benefits in multiple cardiopulmonary parameters, including pulmonary vascular resistance and improvement in Moderate to Vigorous Physical Activity (MVPA) as measured by actigraphy after 16 weeks of chronic treatment. With a total of 145 patients enrolled, the study is powered >90%, (p-value of 0.01) for the primary endpoint of a change in MVPA measured by actigraphy. If approved, INOpulse would become the first therapy to treat a broad fILD population, including patients at low-, intermediate- and high-risk pulmonary hypertension.
Pulmonary Hypertension-Sarcoidosis (PH-Sarc)

Phase 2 Clinical Study: In December 2021, Bellerophon reported positive top-line data from the completed Phase 2 dose escalation study of INOpulse® evaluating the acute hemodynamic benefit of INOpulse® via right heart catheterization for the treatment of pulmonary hypertension associated with sarcoidosis (PH-Sarc). Based on the benefits demonstrated in hemodynamic parameters and favorable safety profile, Bellerophon designed and submitted to the FDA a proposed exploratory Phase 2 double-blinded placebo-controlled study to investigate the safety and efficacy of iNO45 dosed chronically for six months in patients with PH-Sarc. Subsequently, the Company received FDA clearance to conduct the study and Bellerophon is currently assessing the next steps for the study.

First Quarter Ended March 31, 2023, Financial Results:

Total licensing revenue for the three months ended March 31, 2023, was $5.6 million, which is related to the licensing agreement with Baylor BioSciences, Inc.

For the first quarter ended March 31, 2023, the Company reported net income of $2.8 million, or $0.27 per basic and diluted share, compared to a net loss of $5.6 million, or $(0.59) per basic and diluted share, in the first quarter ended March 31, 2022.

Research and development expenses for the first quarter ended March 31, 2023, were $2.6 million, compared to $4.4 million in the first quarter of 2022. The decrease was due to the completion of enrollment in the ongoing Phase 3 REBUILD trial in January 2023.

General and administrative expenses for the first quarter ended March 31, 2023, were $1.6 million, compared to $1.2 million in the first quarter of 2022. The increase was primarily due to an increase in general consulting costs and an increase in stock-based compensation.

Balance Sheet:

As of March 31, 2023, the Company had unrestricted cash and cash equivalents of $15.2 million, compared to unrestricted cash and cash equivalents of $6.9 million as of December 31, 2022. Bellerophon’s capital position as of March 31, 2023, is reflective of the transactions which closed in the first quarter of 2023. These transactions included $1.7 million net proceeds from the sale of the Company’s net operating losses and research and development credits under the State of New Jersey’s Technology Business Tax Certificate Transfer Program in January 2023, net proceeds of approximately $5 million related to the licensing agreement with Baylor BioSciences, and net proceeds of approximately $5 million from the registered direct offering, which closed in March 2023.

About Bellerophon

Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.

dinogreeves PremiumMember

03/20/23 3:14 PM

Post #735

Re: #734: @eur06 - Lol …one needs a flashlight to find the

Its got to be relatively low with those kind of spreads at times.

Bullish

eur06

03/20/23 2:03 PM

Post #734

Re: #733: @dinogreeves - Cricket and frog.. lol

Lol …one needs a flashlight to find the float .
BLPH

dinogreeves PremiumMember

03/20/23 1:55 PM

Post #733

Re: #732: @eur06 - It does jump like a cricket…lol

Cricket and frog.. lol

Bullish

eur06

03/20/23 1:42 PM

Post #732

Re: #731: @dinogreeves - This is must own ticker, a must.

It does jump like a cricket…lol
BLPH

dinogreeves PremiumMember

03/20/23 12:24 PM

Post #731

This is must own ticker, a must. It has 5 times potential from here.

Bullish

eur06

03/20/23 11:57 AM

Post #730

Re: #729: @dinogreeves - identical setup as what NVA*X did. I

That would be fantastic!
Thank you Dino.
BLPH

dinogreeves PremiumMember

03/20/23 11:45 AM

Post #729

Re: #728: @eur06 - Great!

identical setup as what NVA*X did. I believe when the data comes out this will trade easily over 30 dollars.

Bullish

eur06

03/20/23 11:40 AM

Post #728

Re: #727: @dinogreeves - Still here, with all my shares, going no

Great!
BLPH

dinogreeves PremiumMember

03/20/23 11:35 AM

Post #727

Re: #726: @eur06 - It’s happening!!!

Still here, with all my shares, going no where until the data is released, I decide from there.

Bullish

eur06

03/20/23 10:04 AM

Post #726

Re: #724: @dinogreeves - It's positive, yes Tang Capital took a passive

It’s happening!!!
BLPH

eur06

03/18/23 9:01 PM

Post #725

Re: #724: @dinogreeves - It's positive, yes Tang Capital took a passive

Thank you Dino great to know all this!
BLPH

dinogreeves PremiumMember

03/18/23 8:35 PM

Post #724

Re: #723: @eur06 - Positive or negative? Tia

It's positive, yes Tang Capital took a passive position. This is all where it started with NVAX, with direct offering at $2.00 and they walked it up and did more again and again and finally hit 300 dollars, grant it covid era and totally different market, but this is cancer, I think this will do really well with positive data coming out by end of 2nd quarter.

Bullish

eur06

03/18/23 9:20 AM

Post #723

Re: #721: @dinogreeves - Euro, I believe something is happening with BLPH.

Positive or negative? Tia
I did some research found some passive stake by Tang Capital Partners 9.99% which is positive but not short term also they just had an offering dunno anymore, last thing chart seems ready for take off….but that is relative imo.
BLPH

eur06

03/18/23 8:18 AM

Post #722

Re: #721: @dinogreeves - Euro, I believe something is happening with BLPH.

Negative? I don’t know about it then.
BLPH

dinogreeves PremiumMember

03/18/23 1:17 AM

Post #721

Re: #720: @eur06 - Thank you I didn't know going to add

Euro, I believe something is happening with BLPH.

Bullish

eur06

03/17/23 6:41 AM

Post #720

Re: #719: @dinogreeves - No, I mean data.

Thank you I didn't know going to add some.
BLPH

dinogreeves PremiumMember

03/16/23 9:04 PM

Post #719

Re: #718: @eur06 - Lol... you're likely correct and below 7 is

No, I mean data.

Bullish

eur06

03/16/23 6:12 PM

Post #718

Re: #717: @dinogreeves - Every time it wants to run, people sell.

Lol... you're likely correct and below 7 is a great opportunity to enter/add with such a tiny float... Btw do you mean earnings?
BLPH

dinogreeves PremiumMember

03/16/23 5:24 PM

Post #717

Re: #716: @eur06 - About to do it !!!

Every time it wants to run, people sell. They are due for news between now and end of June. So people buy in the hopes of news after hours and when there is no news, they sell only to buy back the next day. That has been the pattern so far.

Bullish

eur06

03/16/23 3:56 PM

Post #716

Re: #714: @dinogreeves - BLPH getting ready to pop. 9.40 blue

About to do it !!!
BLPH

Xunefox

03/14/23 2:05 PM

Post #715

Cmon!!! pop!!

dinogreeves PremiumMember

03/13/23 10:26 AM

Post #714

BLPH getting ready to pop. 9.40 blue skies above.

Bullish

dinogreeves PremiumMember

03/12/23 11:43 PM

Post #713

Futures are ripping hard, only a matter of time before BLPH does a double from there.

dinogreeves PremiumMember

03/11/23 8:12 PM

Post #712

Watch this between Monday-Tuesday, something tells me, it is about to move fast into the teens.

Bullish

dinogreeves PremiumMember

03/10/23 5:13 PM

Post #711

BLPH will do what NVA*X did couple of years back.

Bullish

dinogreeves PremiumMember

03/10/23 4:08 PM

Post #710

BLPH is next weeks runner, runner.

Bullish

Awl416

03/08/23 2:24 PM

Post #709

What a impressive run

Invest-in-America PremiumMember

03/06/23 7:05 PM

Post #708

BLPH: And THIS time around, EASY money all day long!!

Bullish

Awl416

03/06/23 11:52 AM

Post #707

Wild

Awl416

03/03/23 5:21 PM

Post #706

News leak?

Awl416

01/18/23 4:20 PM

Post #705

8k out

delerious1 PremiumMember

01/05/23 12:18 PM

Post #704

Nice to see this one green again...MBGA

Invest-in-America PremiumMember

01/05/23 11:34 AM

Post #703

BLPH: E-Turd will NOT accept orders on this right now! (What's happening here?? And it ain't no SKULL-&-CROSSBONES routine.)

Invest-in-America PremiumMember

01/05/23 9:53 AM

Post #702

BLPH: HUUUUUGE morn. gapper!!! (Be careful.)

alchemytrader Free

01/05/23 9:46 AM

Post #701

Re: #700: @makinezmoney - $BLPH: WOW..... now 2.50

RIP 3.40 chasers.

Bearish

makinezmoney Free

01/05/23 9:13 AM

Post #700

Re: #698: @tw0122 - Thursday King stock of the day 2.16

$BLPH: WOW..... now 2.50

Whatta runnerrrrrrrrrrrrrrrrrrrrr

Excellent call

GO $BLPH

Welsh_Dragon Free

01/05/23 9:12 AM

Post #699

Pre mkt 1.69 was a nice entry.

Where is everyone? This is getting shirts wrecked.

tw0122

01/05/23 8:40 AM

Post #698

Thursday King stock of the day 2.16

delerious1 PremiumMember

10/01/22 7:36 PM

Post #697

Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
09/27/2022 12:30 PM
New study size of 140 patients for the REBUILD Study, without modifying trial objective or endpoints and maintaining power of >90% for the primary endpoint Independent Data Monitoring Committee agreed that the new targeted study size is appropriate Enrollment now expected to conclude in Q1 2023,

delerious1 PremiumMember

10/01/22 7:35 PM

Post #696

Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results
08/15/2022 12:30 PM
WARREN, N.J. , Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial